Rajesh Malik

Filings by Rajesh Malik span 2 companies, the busiest being G1 Therapeutics, Inc. and POINT Biopharma Global Inc. Between 10 May 2021 and 18 September 2024, the trades on record add up to 17 filings.

Both buying and selling appear: 1 purchase worth €24k, against 4 sales worth €48k. On balance, insiders were net sellers of €24k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Other entries cover 5 share grants and 6 option exercises. In 2024 alone, the filings show no purchases and 2 sales.

Most recently, on 18 September 2024, the filings show a share grant in G1 Therapeutics, Inc. The last purchase on record was published on 28 November 2022, which is 1,420 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.